| 名稱 | Ritlecitinib |
| 描述 | Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor with an IC50 of 33.1 nM and does not affect the activity of JAK1/2. |
| 細胞實驗 | Human CD4+ T cells were purified from buffy coat with RosetteSep CD4+ T Cell Enrichment Cocktail and skewed for 6 days with cytokine cocktails (25 ng/mL of IL-6, 25 ng/mL of IL-23, 12.5 ng/mL of IL-1β, 25 ng/mL of IL21, 5 ng/mL of TGFβ1, 10 μg/ml of anti-CD3 antibody (pre-coated on plate surface) and 1 μg/mL of anti-CD28 antibody) in the presence of JAK inhibitors at 10 different concentrations. Supernatants were harvested and the concentrations of IL-17A were determined with MSD assay following the protocol provided by the manufacturer. To study the effect of PF-06651600 on Th17 cells post-differentiation, skewed Th17 cells were washed, rested with X-VIVO 15 medium for overnight and resuspended in medium containing the same concentrations of cytokines as during skewing but without anti-CD3 or anti-CD28 antibodies, in the presence of PF-06651600 at 10 different concentrations for 2 additional days. On Day 9, supernatant was harvested from each well and IL-17A was determined as described above [1]. |
| 激酶實驗 | His-tagged recombinant human TYK2 kinase domain was expressed in SF21/baculovirus and purified using a two-step affinity (Ni-NTA) and size-exclusion (SEC S200) purification method.Test compounds were solubilized in DMSO to a stock concentration of 30 mM.Compounds were diluted in DMSO to create an 11-point half log dilution series with a top concentration of 600 μM.The test compound plate also contained positive control wells containing a known inhibitor to define 100% inhibition and negative control wells containing DMSO to define no inhibition.The compound plates were diluted 1 to 60 in the assay,resulting in a final assay compound concentration range of 10 μM to 100 pM and a final assay concentration of 1.7% DMSO.Test compounds and controls solubilized in 100% DMSO were added (250 nL) to a 384 well polypropylene plate (Matrical) using a non contact acoustic dispenser.Kinase assays were carried out at room temperature in a 15 μL reaction buffer containing 20 mM HEPES,pH 7.4,10 mM magnesium chloride,0.01% bovine serum albumin (BSA),0.0005% Tween 20 and 1mM Dithiothreitol (DTT).Reaction mixtures contained 1 μM of a fluorescently labeled synthetic peptide,at a concentration less than the apparent Michaelis-Menten constant (Km) (5FAM-KKSRGDYMTMQID for JAK1 and TYK2 and FITC-KGGEEEEYFELVKK for JAK2 and JAK3).Reaction mixtures contained adenosine triphosphate (ATP) at either a level equal to the apparent Km for ATP (40 μM for JAK1,4 μM for JAK2,4 μM for JAK3 and 12 μM for TYK2) or at 1 mM ATP.Compound was added to the buffer containing ATP and substrate and immediately after this step the enzyme was added to begin the reaction.The assays were stopped with 15 μL of a buffer containing 180 mM HEPES,pH=7.4,20 mM EDTA,0.2% Coating Reagent,resulting in a final concentration of 10 mM EDTA,0.1% Coating Reagent and 100 mM HEPES,pH=7.4. |
| 動物實驗 | The effect of JAK3 inhibition by PF-06651600 was evaluated in vivo using a therapeutic dosing paradigm in a rat adjuvant-induced arthritis. The efficacy of this molecule was evaluated in three separate studies using successively lower doses. Arthritis was induced by immunization of female Lewis rats (8 to 10 weeks old) via intradermal injection at the base of the tail with complete Freund's adjuvant with three 50 μL injections (15 mg/mL Mycobacterium tuberculosis) in incomplete Freund's adjuvant. Seven days after the initial immunization, the baseline hind paw volume of the immunized rats was measured via plethysmograph. The rats were monitored daily for signs of arthritis including change in body weight and hind paw volume measurement. When individual hind paw volume measurements indicated an increase of 0.2 mL (or greater) in a single hind paw, animals were randomly assigned to a treatment group. Daily treatment with PF-06651600 was administered via oral gavage. Treatment groups for Experiment 1 were: 80, 15, or 6 mg/kg or vehicle (2% Tween 80 /0.5% methylcellulose/deionized water). Treatment groups for Experiment 2 were: 30, 10, and 3 mg/kg or vehicle (0.5% methylcellulose / de-ionized water/ 1 mEQ hydrochloric acid). Treatment groups for Experiment 3 were: 10, 1, 0.3 and 0.1 mg/kg or vehicle (0.5% methylcellulose/de-ionized water/ 1 mEQ hydrochloric acid). Dosing began once individuals were enrolled into respective groups. Treatment continued for 7 days. At the conclusion of the study, whole blood was taken at 15 minutes post-dose (peak concentration in plasma) for analysis of STAT phosphorylation, and plasma was taken for exposure concentration in PF-06651600 dosed groups [1]. |
| 體外活性 | 方法：在體外生理上相關的ATP濃度（1mM）存在的情況下，研究Ritlecitinib對JAK1/2/3激酶的活性影響。
結果：Ritlecitinib抑制JAK3激酶活性的IC50為33.1 nM，但對JAK1、JAK2和TYK2沒有活性(IC50 > 10000 nM)。[1]
方法：通過流式細胞術(FACS)對f -06651600在人全血總淋巴細胞中的效力和選擇性進行了評價。
結果：Ritlecitinib抑制IL-2、IL-4、IL-7和IL-15誘導的STAT5磷酸化的IC50值分別為244、340、407和266 nM；Ritlecitinib抑制IL-21誘導的STAT3磷酸化的IC50值為355 nM。[1] |
| 體內(nèi)活性 | 方法：Ritlecitinib (PF-06651600) （3,10,30 mg/kg,口服，每天一次）治療關節(jié)炎和腦脊髓炎兩種嚙齒動物模型小鼠，研究對其影響。
結果：Ritlecitinib治療顯著降低了通過體積描記儀測量的小鼠足跖腫脹的疾病嚴重性；在大鼠佐劑性關節(jié)炎(AIA)模型中，Ritlecitinib減少了足跖腫脹，未結合EC50為169 nM。[1] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 130 mg/mL (455.60 mM)
|
| 關鍵字 | Janus kinase | Inhibitor | inhibit | JAK | Ritlecitinib | PF06651600 | PF 06651600 |
| 相關產(chǎn)品 | JAK-IN-10 | Tofacitinib Citrate | Deucravacitinib | RO8191 | Ruxolitinib | KW-2449 | TAK-901 | CEP-33779 | Baricitinib | Fedratinib | Ruxolitinib phosphate | Delgocitinib |
| 相關庫 | 抑制劑庫 | 激酶抑制劑庫 | EMA 上市藥物庫 | 抗衰老化合物庫 | FDA 上市藥物庫 | 酪氨酸激酶分子庫 | 藥物功能重定位化合物庫 | FDA 上市激酶抑制劑庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |